Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

被引:1020
作者
Olive, KP
Tuveson, DA
Ruhe, ZC
Yin, B
Willis, NA
Bronson, RT
Crowley, D
Jacks, T
机构
[1] MIT, Ctr Canc Res, Cambridge, MA 02139 USA
[2] Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA
[3] Tufts Univ, Sch Vet, Dept Biomed Sci, North Grafton, MA 01536 USA
[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
关键词
D O I
10.1016/j.cell.2004.11.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 tumor suppressor gene is commonly altered in human tumors, predominantly through missense mutations that result in accumulation of mutant p53 protein. These mutations may confer dominant-negative or gain-of-function properties to p53. To ascertain the physiological effects of p53 point mutation, the structural mutant p53(R172H) and the contact mutant p53(R270H) (codons 175 and 273 in humans) were engineered into the endogenous p53 locus in mice. p53(R270H/+) and p53(R172H/-) mice are models of Li-Fraumeni Syndrome; they developed allele-specific tumor spectra distinct from p53(+/-) mice. In addition, p53(R270H/-) and p53(R172H/-) mice developed novel tumors compared to p53(-/-) mice, including a variety of carcinomas and more frequent endothelial tumors. Dominant effects that varied by allele and function were observed in primary cells derived from p53(R270H/+) and p53(R172H/+), mice. These results demonstrate that point mutant p53 alleles expressed under physiological control have enhanced oncogenic potential beyond the simple loss of p53 function.
引用
收藏
页码:847 / 860
页数:14
相关论文
共 56 条
[11]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[12]   MICE DEFICIENT FOR P53 ARE DEVELOPMENTALLY NORMAL BUT SUSCEPTIBLE TO SPONTANEOUS TUMORS [J].
DONEHOWER, LA ;
HARVEY, M ;
SLAGLE, BL ;
MCARTHUR, MJ ;
MONTGOMERY, CA ;
BUTEL, JS ;
BRADLEY, A .
NATURE, 1992, 356 (6366) :215-221
[13]  
Eid H, 1999, ANTICANCER RES, V19, P3485
[14]   PARTICIPATION OF P53 CELLULAR TUMOR-ANTIGEN IN TRANSFORMATION OF NORMAL EMBRYONIC-CELLS [J].
ELIYAHU, D ;
RAZ, A ;
GRUSS, P ;
GIVOL, D ;
OREN, M .
NATURE, 1984, 312 (5995) :646-649
[15]   THE P53 PROTO-ONCOGENE CAN ACT AS A SUPPRESSOR OF TRANSFORMATION [J].
FINLAY, CA ;
HINDS, PW ;
LEVINE, AJ .
CELL, 1989, 57 (07) :1083-1093
[16]  
FORRESTER K, 1995, ONCOGENE, V10, P2103
[17]   A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain [J].
Gaiddon, C ;
Lokshin, M ;
Ahn, J ;
Zhang, T ;
Prives, C .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1874-1887
[18]   DIFFERENT TUMOR-DERIVED P53 MUTANTS EXHIBIT DISTINCT BIOLOGICAL-ACTIVITIES [J].
HALEVY, O ;
MICHALOVITZ, D ;
OREN, M .
SCIENCE, 1990, 250 (4977) :113-116
[19]   A MUTANT P53 TRANSGENE ACCELERATES TUMOR-DEVELOPMENT IN HETEROZYGOUS BUT NOT NULLIZYGOUS P53 DEFICIENT MICE [J].
HARVEY, M ;
VOGEL, H ;
MORRIS, D ;
BRADLEY, A ;
BERNSTEIN, A ;
DONEHOWER, LA .
NATURE GENETICS, 1995, 9 (03) :305-311
[20]   AIS is an oncogene amplified in squamous cell carcinoma [J].
Hibi, K ;
Trink, B ;
Patturajan, M ;
Westra, WH ;
Caballero, OL ;
Hill, DE ;
Ratovitski, EA ;
Jen, J ;
Sidransky, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5462-5467